HOW TO MANAGE DIABETIC KETOACIDOSIS: FROM DIAGNOSIS TO TREATMENT

Diabetic ketoacidosis (DKA) is an acute, life-threatening complication of diabetes mellitus characterized by hyperglycemia, ketosis, and a high anion gap metabolic acidosis. Primarily affecting individuals with type 1 diabetes, it can also occur in type 2 diabetes under severe stress. Early recognition and aggressive management are paramount to improve patient outcomes.

Precipitating Factors of Diabetic Ketoacidosis

DKA arises from a profound insufficiency of insulin, which leads to uncontrolled glucose production and unchecked fat breakdown, resulting in the accumulation of ketone bodies. The absence or severe deficit of insulin, coupled with an increase in counter-regulatory hormones (glucagon, catecholamines, cortisol, growth hormone), drives the pathophysiology. Understanding these triggers is crucial for prevention and management.

A. Infection (Most Common Trigger): Infections are the leading precipitating factor for DKA, accounting for 30-50% of cases. Systemic inflammatory responses to infections (e.g., pneumonia, urinary tract infections, sepsis, gastroenteritis) profoundly increase the release of counter-regulatory hormones. These hormones antagonize insulin’s action and stimulate glucose production (gluconeogenesis and glycogenolysis), leading to hyperglycemia. Concurrently, they promote lipolysis, increasing the availability of free fatty acids for ketogenesis. Even mild infections can trigger DKA in susceptible individuals if insulin doses are not adjusted appropriately.

B. Non-compliance or Inadequate Insulin Therapy: This is a significant factor, particularly in adolescents and young adults with type 1 diabetes.

• Missed Insulin Doses: Intentional omission (e.g., due to fear of weight gain, psychological distress, or financial constraints) or accidental oversight of insulin doses can rapidly lead to DKA.
• Insulin Pump Malfunction: Obstruction or dislodgement of the insulin catheter, pump failure, or battery depletion can interrupt continuous basal insulin delivery, leading to acute insulin deficiency.
• Under-dosing: Insufficient insulin doses, especially during periods of increased stress or illness, can be inadequate to control blood glucose and prevent ketosis.

C. New Diagnosis of Type 1 Diabetes: DKA is the initial presentation in approximately 25-30% of children and some adults newly diagnosed with type 1 diabetes. In these cases, the autoimmune destruction of pancreatic beta cells has progressed to a critical point where insulin production is virtually absent, leading to the abrupt onset of DKA symptoms.

D. Acute Medical Illnesses: Severe physiological stress can precipitate DKA due to the release of counter-regulatory hormones, even in patients who typically manage their diabetes well.

• Myocardial Infarction: Cardiac ischemia triggers significant stress hormone release.
• Stroke: Brain injury and systemic stress response.
• Pancreatitis: Inflammation of the pancreas can impair insulin secretion and induce a systemic stress response.
• Trauma/Surgery: Physical injury and surgical stress elevate counter-regulatory hormone levels.

E. Medications: Certain medications can exacerbate hyperglycemia and/or promote ketogenesis.

• Glucocorticoids (Steroids): These drugs directly increase hepatic glucose production and induce insulin resistance.
• Thiazide Diuretics: Can impair insulin secretion and increase glucose levels.
• Sympathomimetics: Drugs like dobutamine or terbutaline can increase glucose.
• Second-Generation Antipsychotics: Some can lead to weight gain and insulin resistance.
• Sodium-Glucose Co-transporter 2 (SGLT2) Inhibitors: While effective for glucose control, SGLT2 inhibitors (e.g., empagliflozin, canagliflozin, dapagliflozin) can cause “euglycemic DKA,” where DKA occurs at blood glucose levels below 250 mg/dL. This is due to increased renal glucose excretion (leading to lower glucose), but increased glucagon levels, lipolysis, and ketogenesis are still promoted.

F. Alcohol Abuse: Chronic alcohol consumption can deplete glycogen stores, impair gluconeogenesis, and lead to nutritional deficiencies. In combination with binge drinking, it can also lead to “alcoholic ketoacidosis,” which shares features with DKA but typically lacks severe hyperglycemia. However, alcohol can also directly precipitate DKA in diabetic individuals by impairing their ability to manage insulin.

G. Eating Disorders or Dietary Non-adherence: In patients with diabetes, particularly type 1, restrictive eating disorders like bulimia nervosa or anorexia nervosa can be associated with insulin omission to promote weight loss, leading to recurrent DKA episodes.

Diagnostic Workup

Diagnosing DKA involves a combination of clinical assessment and laboratory confirmation. The diagnostic criteria established by the American Diabetes Association (ADA) include hyperglycemia, metabolic acidosis, and ketonemia.

A. Clinical Presentation: Patients typically present with symptoms evolving over hours to days.

• Hyperglycemic Symptoms: Polyuria (frequent urination), polydipsia (excessive thirst), polyphagia (increased hunger), and weight loss.
• Dehydration Signs: Tachycardia, hypotension, dry mucous membranes, decreased skin turgor, orthostatic changes.
• Gastrointestinal Symptoms: Nausea, vomiting, and abdominal pain (can be severe, mimicking acute abdomen, especially in children).
• Acidosis Symptoms: Kussmaul respirations (deep, rapid breathing, a compensatory mechanism for metabolic acidosis), fruity breath odor (due to acetone exhalation).
• Neurological Changes: Lethargy, confusion, stupor, or coma, particularly with severe acidosis and hyperosmolarity.

B. Laboratory Investigations:

1. Blood Glucose:
   • Typically > 250 mg/dL (13.9 mmol/L).
   • Crucially, in euglycemic DKA (often seen with SGLT2 inhibitors, pregnancy, or prolonged fasting), blood glucose may be < 250 mg/dL.
2. Arterial Blood Gas (ABG) or Venous Blood Gas (VBG):
   • pH: < 7.3 (mild DKA: 7.25-7.30, moderate: 7.00-7.24, severe: < 7.00). VBG pH is typically 0.02-0.03 units lower than ABG pH and can be used as a reasonable substitute.
   • Bicarbonate (HCO3-): < 18 mEq/L (mild: 15-18, moderate: 10-14, severe: < 10 mEq/L).
3. Serum Ketones:
   • Positive for beta-hydroxybutyrate, which is the predominant ketone body in DKA. A level > 3 mmol/L is diagnostic. Nitroprusside tests (urine dipsticks) primarily detect acetoacetate and acetone, which may underestimate the severity of ketosis, especially during improvement phases when beta-hydroxybutyrate converts back to acetoacetate.
4. Urine Ketones:
   • Moderate to large positive (> 2+). Useful for initial screening but less quantitative than serum beta-hydroxybutyrate.
5. Electrolytes (Na, K, Cl, Bicarb):
   • Sodium (Na): Often appears falsely low (pseudohyponatremia) due to the osmotic effect of high glucose drawing water into the extracellular space. Corrected sodium = measured Na + [1.6 * (Glucose – 100) / 100].
   • Potassium (K): Serum potassium can be normal or high on presentation despite total body potassium depletion due to acidosis and insulin deficiency shifting K out of cells. This will rapidly fall with insulin therapy.
   • Chloride (Cl): Important for anion gap calculation.
   • Anion Gap (AG): Calculated as [Na – (Cl + HCO3-)], typically > 12 mEq/L in DKA, reflecting the accumulation of unmeasured anions (ketone bodies). This is a critical marker for monitoring DKA resolution.
6. Blood Urea Nitrogen (BUN) and Creatinine:
   • Elevated levels indicate dehydration and prerenal azotemia.
7. Complete Blood Count (CBC):
   • Leukocytosis (elevated white blood cell count) is common due to stress, even in the absence of infection. However, a marked shift to immature forms or very high counts should raise suspicion for an underlying infection.
8. Serum Osmolality:
   • Often elevated due to hyperglycemia and dehydration. Calculated osmolality = 2*Na + Glucose/18 + BUN/2.8. High levels contribute to neurological symptoms.
9. Investigations for Precipitating Factors:
   • Urinalysis + Urine Culture: To rule out urinary tract infection.
   • Chest X-ray: If pulmonary infection (pneumonia) is suspected.
   • Blood Cultures/Sputum Cultures: If fever or signs of systemic infection are present.
   • Electrocardiogram (ECG): To assess for cardiac ischemia (if MI suspected) and monitor for T-wave changes associated with hyper- or hypokalemia.
   • Serum Amylase/Lipase: If pancreatitis is suspected due to abdominal pain.

Treatment of Diabetic Ketoacidosis

Management of DKA is a medical emergency requiring a systematic, step-by-step approach focusing on fluid replacement, insulin administration, electrolyte correction, and identification/treatment of precipitating causes. Close monitoring is essential throughout the process.

A. Fluid Replacement (Most Critical Initial Step): The primary goal is to restore intravascular volume and renal perfusion, reduce counter-regulatory hormones, and enhance glucose excretion.

• Initial Bolus: Administer 1 to 1.5 liters of 0.9% sodium chloride (isotonic saline) intravenously over the first hour in adults (10-20 mL/kg in children). If the patient is in hypovolemic shock, a more rapid infusion may be necessary.
• Subsequent Fluids: After the initial bolus, adjust subsequent fluid rates and tonicity based on hydration status, corrected serum sodium, and glucose levels.
  • If corrected serum sodium is normal or high: Switch to 0.45% sodium chloride (hypotonic saline) at 250-500 mL/hr. This helps reduce serum osmolality and provides free water.
  • If corrected serum sodium is low: Continue with 0.9% sodium chloride at 250-500 mL/hr to maintain intravascular volume without further worsening hyponatremia.
• When Glucose Reaches 200-250 mg/dL: Add dextrose to the intravenous fluids (e.g., D5 0.45% NaCl) at 150-250 mL/hr. This prevents hypoglycemia as insulin therapy continues to lower blood glucose, while also allowing continued fluid and electrolyte repletion necessary for DKA resolution.

B. Insulin Therapy: Insulin therapy is crucial to reverse the metabolic acidosis by suppressing lipolysis and ketogenesis, and by facilitating glucose uptake into cells. It should be initiated after the initial fluid bolus and only when serum potassium is confirmed to be > 3.3 mEq/L.

• Intravenous Regular Insulin Infusion: Start a continuous intravenous infusion of regular insulin at 0.1 units/kg/hr. A bolus of insulin is generally not recommended as it carries an increased risk of hypoglycemia and hypokalemia without significant additional benefit.
• Rate Adjustment: The goal is to decrease blood glucose by 50-75 mg/dL per hour. If glucose does not fall at this rate, the insulin infusion can be doubled hourly until the target glucose drop is achieved.
• Continuation Criteria: Continue insulin infusion until DKA is resolved (anion gap normalizes < 12 mEq/L, serum bicarbonate > 18 mEq/L, and patient is able to tolerate oral intake).
• Transition to Subcutaneous Insulin: Once DKA is resolved, transition to a multi-dose subcutaneous insulin regimen. To prevent rebound ketosis, overlap the intravenous insulin infusion with subcutaneous insulin administration for 1-2 hours before discontinuing the IV insulin.

C. Potassium Replacement: Despite normal or high serum potassium (K+) levels at presentation, patients with DKA have a significant total body potassium deficit. Insulin therapy and correction of acidosis drive potassium back into cells, leading to a rapid and potentially dangerous fall in serum K+.

• **If K+ < 3.3 mEq/L:** **HOLD INSULIN** and administer potassium chloride (e.g., 20-40 mEq/hr) until K+ is > 3.3 mEq/L. Restart insulin only after potassium is adequately repleted.
• If K+ 3.3-5.2 mEq/L: Add potassium chloride to the intravenous fluids (typically 20-30 mEq K per liter of IV fluid) to maintain serum K+ within the normal range.
• If K+ > 5.2 mEq/L: Do not add potassium initially, but monitor serum K+ every 2 hours as levels will fall.

D. Bicarbonate Therapy: Sodium bicarbonate therapy is generally NOT RECOMMENDED in DKA unless the acidosis is extremely severe (pH < 6.9) and associated with hemodynamic instability or life-threatening hyperkalemia.

• Risks: Bicarbonate administration can paradoxically worsen CNS acidosis (due to slower passage across the blood-brain barrier compared to CO2), precipitate cerebral edema, and worsen hypokalemia.
• Natural Resolution: The acidosis typically resolves with fluid and insulin therapy as ketone body production ceases and renal excretion improves.

E. Phosphate Replacement: Total body phosphate depletion occurs in DKA, but routine phosphate replacement is not recommended due to potential risks (e.g., hypocalcemia, tetany).

• Consider if: Serum phosphate < 1.0 mg/dL, with cardiac dysfunction, respiratory depression, or severe anemia. It is usually administered as potassium phosphate.

F. Identification and Treatment of Precipitating Factors: Simultaneously with metabolic correction, a thorough search for the underlying cause of DKA is essential.

• Infection: Promptly initiate appropriate antibiotics after obtaining cultures.
• Non-compliance: Provide patient education and counseling, potentially involving a diabetes educator or social worker.
• New Diagnosis: Educate the patient and family on diabetes management.
• Medication Review: Adjust or discontinue medications contributing to DKA if possible.

G. Monitoring: Intensive monitoring is crucial during DKA management.

• Blood Glucose: Hourly.
• Electrolytes (Na, K, Cl, Bicarb), ABG/VBG, Serum Ketones: Every 2-4 hours initially, then less frequently as stability improves.
• Fluid Balance: Intake and output.
• Vital Signs: Hourly (heart rate, blood pressure, respiratory rate, temperature).
• Mental Status: Regularly assess for changes that could indicate worsening cerebral edema.

Conclusion

Diabetic ketoacidosis is a complex and potentially fatal complication of diabetes, demanding prompt and meticulous management. A clear understanding of its precipitating factors, the systematic diagnostic workup, and the evidence-based treatment protocol – centered on fluid resuscitation, insulin therapy, and electrolyte correction – is essential for all healthcare professionals. Continuous monitoring and a diligent search for the underlying cause are integral to ensuring successful recovery and preventing recurrence.

References

1. Kitabchi, A. E., Umpierrez, G. E., Miles, J. M., & Fisher, J. N. (2009). Hyperglycemic Crises in Adult Patients With Diabetes. Diabetes Care, 32(7), 1335–1343.
2. American Diabetes Association. (2023). 16. Diabetes Care in the Hospital: Standards of Care in Diabetes—2023. Diabetes Care, 46(Supplement_1), S283–S292.
3. Umpierrez, G. E., Kitabchi, A. E., & Gosmanov, A. R. (2023, March 14). Diabetic ketoacidosis and hyperosmolar hyperglycemic state in adults: Treatment. UpToDate. Retrieved from https://www.uptodate.com/contents/diabetic-ketoacidosis-and-hyperosmolar-hyperglycemic-state-in-adults-treatment
4. Fayfman, M., Pasquel, F. J., & Umpierrez, G. E. (2017). Management of Hyperglycemic Crises: Diabetic Ketoacidosis and Hyperglycemic Hyperosmolar State. Medical Clinics of North America, 101(3), 543–554.
5. Gosmanov, A. R., & Kitabchi, A. E. (2020). Diabetic Ketoacidosis. In J. E. Hall & M. J. Hall (Eds.), Guyton and Hall Textbook of Medical Physiology (14th ed., pp. 989-992). Elsevier.
6. Dhatariya, K. K., Glaser, N. S., Nyenwe, E. A., & Umpierrez, G. E. (2020). Diabetic ketoacidosis and hyperosmolar hyperglycemic state in adults: a consensus statement from the American Diabetes Association. Diabetes Care, 43(8), 1675–1696.